These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 17708548)
41. Primary vaginal and pelvic floor reconstruction at the time of pelvic exenteration: a study of morbidity. Jurado M; Bazán A; Elejabeitia J; Paloma V; Martínez-Monge R; Alcázar JL Gynecol Oncol; 2000 May; 77(2):293-7. PubMed ID: 10785481 [TBL] [Abstract][Full Text] [Related]
42. Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis. Bizzarri N; Chiantera V; Loverro M; Sozzi G; Perrone E; Gueli Alletti S; Costantini B; Gallotta V; Tortorella L; Fagotti A; Fanfani F; Ercoli A; Scambia G; Vizzielli G Int J Gynecol Cancer; 2023 Feb; 33(2):190-197. PubMed ID: 36593063 [TBL] [Abstract][Full Text] [Related]
43. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca--a single institution's experience over 16 years. Tan KK; Pal S; Lee PJ; Rodwell L; Solomon MJ Colorectal Dis; 2013; 15(10):1227-31. PubMed ID: 23714581 [TBL] [Abstract][Full Text] [Related]
44. Long-term outcomes of pelvic exenterations for gynecological malignancies: a single-center retrospective cohort study. Yu JH; Tong CJ; Huang QD; Ye YL; Chen G; Li H; Wen YS; Yang F; Luo NB; Xu GY; Xiong Y BMC Cancer; 2024 Jan; 24(1):88. PubMed ID: 38229045 [TBL] [Abstract][Full Text] [Related]
45. Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Benn T; Brooks RA; Zhang Q; Powell MA; Thaker PH; Mutch DG; Zighelboim I Gynecol Oncol; 2011 Jul; 122(1):14-8. PubMed ID: 21444105 [TBL] [Abstract][Full Text] [Related]
47. Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature. Bizzarri N; Chiantera V; Ercoli A; Fagotti A; Tortorella L; Conte C; Cappuccio S; Di Donna MC; Gallotta V; Scambia G; Vizzielli G J Minim Invasive Gynecol; 2019; 26(7):1316-1326. PubMed ID: 30611973 [TBL] [Abstract][Full Text] [Related]
48. [Pelvic exenteration of advanced gynecological malignacies: a report of 18 cases]. Zhang Z; Zang R; Chen J Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):288-90. PubMed ID: 11775910 [TBL] [Abstract][Full Text] [Related]
49. Pelvic exenteration for gynecological malignancies: an analysis of 15 cases operated on at a single institution. Mäenpää JU; Kangasniemi K; Luukkaala T Acta Obstet Gynecol Scand; 2010; 89(2):279-83. PubMed ID: 19916881 [TBL] [Abstract][Full Text] [Related]
50. Indications for primary and secondary exenterations in patients with cervical cancer. Marnitz S; Köhler C; Müller M; Behrens K; Hasenbein K; Schneider A Gynecol Oncol; 2006 Dec; 103(3):1023-30. PubMed ID: 16890276 [TBL] [Abstract][Full Text] [Related]
51. Pelvic exenterations for gynecologic cancers: A retrospective analysis of a 30-year experience in a cancer center. Knight S; Lambaudie E; Sabiani L; Mokart D; Provansal M; Tallet A; Houvenaeghel G Eur J Surg Oncol; 2018 Dec; 44(12):1929-1934. PubMed ID: 30262326 [TBL] [Abstract][Full Text] [Related]
52. Quality of life after pelvic exenteration for gynecologic cancer: Findings from a qualitative study. Nelson AM; Albizu-Jacob A; Fenech AL; Chon HS; Wenham RM; Donovan KA Psychooncology; 2018 Oct; 27(10):2357-2362. PubMed ID: 29956389 [TBL] [Abstract][Full Text] [Related]
53. Primary vaginal reconstruction at the time of pelvic exenteration for gynecologic cancer: morbidity revisited. Jurado M; Bazán A; Alcázar JL; Garcia-Tutor E Ann Surg Oncol; 2009 Jan; 16(1):121-7. PubMed ID: 18941843 [TBL] [Abstract][Full Text] [Related]
54. Reconstruction of the pelvic floor and the vagina after total pelvic exenteration using the transverse musculocutaneous gracilis flap. Kaartinen IS; Vuento MH; Hyöty MK; Kallio J; Kuokkanen HO J Plast Reconstr Aesthet Surg; 2015 Jan; 68(1):93-7. PubMed ID: 25305732 [TBL] [Abstract][Full Text] [Related]
55. The role of pelvic exenteration for treatment of pelvic malignancy--a nine-year experience. Wydra D; Emerich J; Ciach K; Sawicki S; Marciniak A Eur J Gynaecol Oncol; 2005; 26(4):418-22. PubMed ID: 16122192 [TBL] [Abstract][Full Text] [Related]
57. Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration. Bogani G; Signorelli M; Ditto A; Martinelli F; Casarin J; Mosca L; Leone Roberti Maggiore U; Chiappa V; Lorusso D; Raspagliesi F Int J Gynecol Cancer; 2018 Jun; 28(5):975-982. PubMed ID: 29683876 [TBL] [Abstract][Full Text] [Related]
58. Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer. Bhangu A; Ali SM; Brown G; Nicholls RJ; Tekkis P Ann Surg; 2014 Feb; 259(2):315-22. PubMed ID: 23478530 [TBL] [Abstract][Full Text] [Related]
59. Pelvic exenteration: surgical aspects and analysis of early and late morbidity in a series of 106 patients. De Wever I Acta Chir Belg; 2011; 111(5):273-81. PubMed ID: 22191127 [TBL] [Abstract][Full Text] [Related]
60. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. Milne T; Solomon MJ; Lee P; Young JM; Stalley P; Harrison JD; Austin KK Dis Colon Rectum; 2014 Oct; 57(10):1153-61. PubMed ID: 25203370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]